NewsEvents

Your Yourlocation: Home > Treatment with tiotropium bromide(136310-93-5), salmeterol and inhaled corticosteroid fluticasone propionate triple therapy

The double-blind study, titled WISDOM, eliminates inhaled corticosteroids in the management of bronchodilators. More than 2,400 patients received tiotropium bromide(136310-93-5) (18 μg once daily), salmeterol (50 μg twice daily) and inhaled glucocorticoid fluticasone propionate (500μg twice daily) triple therapy. The lead-in period was 6 weeks and all three drugs were used during the lead-in period. After the lead-in period, patients were randomized to receive triple therapy or gradually reduce the amount of fluticasone over a 12-week period.

The current recommendation for patients with severe COPD and frequent seizures is the combination of inhaled corticosteroids and long-acting bronchodilators, but new drugs have prompted some to question this recommendation.

"We now have long-acting beta agonists and long-acting muscarinic receptor antagonists," said Magnussen, MD, a leading investigator at the Lung Clinic Grosshansdorf Lung Institute in Germany." Because doubly bronchodilator drugs have been used for many years, we question whether there are differences between patients who use dual bronchodilator and inhaled corticosteroids and those who use only bronchodilators after phasing out inhaled corticosteroids.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved